Ocular Therapeutix

What Ocular Therapeutix does

Ocular Therapeutix is a Bedford, Massachusetts-based, NASDAQ-listed biopharmaceutical company (OCUL) founded in 2006 that develops and commercializes ophthalmic therapies built on its proprietary ELUTYX bioresorbable hydrogel platform, which enables sustained, localized drug delivery for up to 12 months. Its commercial portfolio consists of DEXTENZA, an FDA-approved dexamethasone ophthalmic insert for post-surgical ocular inflammation and pain, and ReSure Sealant for sealing corneal incisions after cataract surgery; both leverage the same hydrogel technology. The company's lead pipeline asset is AXPAXLI (OTX-TKI), an intravitreal axitinib hydrogel in Phase 3 development for wet age-related macular degeneration, with the SOL-1 superiority trial meeting its primary endpoint at p=0.0006 and an NDA submission planned for Q4 2026 under the 505(b)(2) pathway, plus HELIOS-3 underway in non-proliferative diabetic retinopathy and OTX-TIC (travoprost hydrogel) in Phase 2 for glaucoma. Ocular generates revenue through DEXTENZA product sales distributed via specialty pharmacies to ophthalmic surgeons, with a US-based field sales force and medical science liaison team targeting retina specialists and ophthalmologists in anticipation of an AXPAXLI launch that would target the $15B global branded anti-VEGF market.

Name

Ocular Therapeutix

Legal name

Ocular Therapeutix, Inc.

Website

https://ocutx.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

251–500 employees

Short description

Ocular Therapeutix is a Bedford, MA-based biopharmaceutical company that develops ophthalmic therapeutics on its ELUTYX bioresorbable hydrogel platform, currently commercializing DEXTENZA and advancing lead pipeline asset AXPAXLI (an axitinib intravitreal hydrogel) through Phase 3 trials for wet AMD and diabetic retinopathy.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)

akta.pro primary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

akta.pro secondary industries

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Ophthalmic therapeutics
• Bioresorbable hydrogel
• Retinal disease treatment
• Sustained drug delivery
• Intravitreal injection

Headquarters

HQ city

Bedford

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. DEXTENZA Product Sales: The company generates commercial revenue from sales of DEXTENZA (dexamethasone ophthalmic insert), an FDA-approved product for intracanalicular use. DEXTENZA is a registered trademark of Ocular Therapeutix.
2. AXPAXLI (pre-commercial): AXPAXLI is in Phase 3 clinical trials and not yet generating revenue. The company plans to submit an NDA in Q4 2026 for wet AMD. Once approved, this will become a significant revenue driver.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Ocular Therapeutix develops, manufactures, and commercializes ophthalmic therapeutics using its proprietary ELUTYX bioresorbable hydrogel technology for sustained, localized drug delivery. The company sells DEXTENZA (dexamethasone ophthalmic insert) for post-surgical ocular inflammation, ReSure Sealant for corneal incision closure, and is developing the lead investigational product AXPAXLI (axitinib intravitreal hydrogel) for wet AMD and diabetic retinopathy, plus OTX-TIC for glaucoma.

Product overview

Ocular Therapeutix is an integrated biopharmaceutical company focused on retina treatments, operating as a single-platform company built around its proprietary ELUTYX bioresorbable hydrogel technology. The company has one FDA-approved commercial product, DEXTENZA (dexamethasone ophthalmic insert) for post-operative ocular inflammation, and ReSure Sealant for corneal incision sealing. The lead investigational product is AXPAXLI (axitinib intravitreal hydrogel), currently in Phase 3 clinical trials for wet age-related macular degeneration and diabetic retinopathy. Additional pipeline products include OTX-TIC (travoprost intracameral hydrogel) in Phase 2 for glaucoma, both leveraging the ELUTYX platform for sustained drug delivery.

Differentiator

Problem solved

Functional benefit

Brands

• DEXTENZA: FDA-approved dexamethasone ophthalmic insert for intracanalicular use
• AXPAXLI
• ELUTYX
• OTX-TIC

Products and services

• DEXTENZA (dexamethasone ophthalmic insert) FDA-approved dexamethasone ophthalmic insert administered intracanalicularly for the treatment of ocular inflammation and pain following ophthalmic surgery. Sold to ophthalmic surgeons and healthcare providers as a commercial specialty pharmaceutical product.
• ReSure Sealant FDA-approved ophthalmic sealant used to seal corneal incisions following cataract surgery, preventing fluid leakage after intraocular procedures. Sold to cataract surgeons and ophthalmic surgery centers.
• AXPAXLI (OTX-TKI, axitinib intravitreal hydrogel) Investigational axitinib intravitreal hydrogel administered by injection, currently in Phase 3 clinical trials (SOL-1 met primary endpoint p=0.0006; SOL-R ongoing) for wet AMD and Phase 3 trials (HELIOS-2, HELIOS-3) for diabetic retinopathy. Combines a highly potent and selective tyrosine kinase inhibitor with the ELUTYX bioresorbable hydrogel technology for continuous drug delivery for up to 12 months, targeting reduction of injection frequency from every 1-3 months to 1-2 times per year. Intended for retina specialists treating wet AMD and diabetic retinopathy patients.
• OTX-TIC (travoprost intracameral hydrogel) Investigational travoprost intracameral hydrogel administered by intracameral injection for the treatment of glaucoma and ocular hypertension, currently in Phase 2 clinical trials. Designed to provide extended duration of action for long-term reduction and maintenance of intraocular pressure with once-yearly dosing potential. Uses the ELUTYX proprietary hydrogel technology platform. Intended for ophthalmologists treating glaucoma and ocular hypertension patients.

Quantifiable outcome

• 74.1% of AXPAXLI subjects maintained vision at Week 36 vs 55.8% for aflibercept (p=0.0006)
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Alcon: Alcon is a global ophthalmic pharmaceutical and medical device leader with a broad portfolio including surgical and pharmaceutical products for retinal disease and glaucoma. Comparable as a major ophthalmic commercial infrastructure competitor, with multiple Ocular Therapeutix executives having Alcon backgrounds.
• Genentech (Roche): Genentech developed and commercializes LUCENTIS (ranibizumab), another major anti-VEGF therapy for wet AMD and diabetic retinopathy. As a foundational retinal disease franchise, LUCENTIS represents the standard of care that AXPAXLI aims to disrupt with its reduced injection frequency.
• Bausch + Lomb: Bausch + Lomb is a diversified ophthalmic company with pharmaceutical, surgical, and consumer vision care products, including treatments for retinal disease and glaucoma. Comparable as a broad incumbent competing across multiple ophthalmic segments, with former Ocular regulatory officer Art Ciociola having held roles at Bausch + Lomb.
• Regeneron Pharmaceuticals: Regeneron commercializes EYLEA (aflibercept), the dominant anti-VEGF therapy for wet AMD that AXPAXLI demonstrated superiority over in SOL-1. Multiple Ocular Therapeutix executives (David Robinson, Steve Meyers, Namrata Saroj) previously held commercial roles at Regeneron, making it a direct comparand for the wet AMD market opportunity.
• IVERIC Bio (Astellas Pharma): IVERIC Bio (acquired by Astellas for $5.9B in 2023) developed IZERVAY for geographic atrophy. Multiple Ocular executives including CEO Pravin Dugel and CFO Todd Anderman previously led IVERIC Bio, providing direct comparability for ophthalmic biopharma strategy and valuation.

Direct peers

• Clearside Biomedical: Clearside Biomedical develops ophthalmic drug delivery technologies including suprachoroidal injection platforms for retinal and choroidal diseases. Comparable as a specialty ophthalmic drug delivery company targeting retinal disease with innovative delivery mechanisms.
• Kodiak Sciences: Kodiak Sciences is developing novel therapeutics for retinal diseases including wet AMD with extended-duration formulations targeting reduced injection burden. Directly comparable as a clinical-stage ophthalmology company pursuing improved anti-VEGF durability.
• EyePoint Pharmaceuticals: EyePoint develops sustained-release ocular drug delivery products including Duravyu for retinal disease, making it the most direct competitor to Ocular Therapeutix's AXPAXLI. Both companies target wet AMD and diabetic retinopathy with extended-duration intravitreal therapies and are currently in active litigation.

Emerging players

• Outlook Therapeutics: Outlook Therapeutics develops ONS-5010/LYTENAVA (bevacizumab), an ophthalmic formulation for wet AMD currently under FDA review. Comparable as an emerging ophthalmic biopharmaceutical company targeting the wet AMD anti-VEGF market.
• Adverum Biotechnologies: Adverum is developing gene therapies for ocular diseases including wet AMD with single-administration treatment potential. Comparable as an emerging retinal disease player with a one-time, long-duration treatment approach that competes on injection burden reduction.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ocular-therapeutix
• Facebookfacebook.com/OcularTherapeutix
• YouTubeyoutube.com/channel/UCxxxx
• Xx.com/ocutx

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds13 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ocular Therapeutix